

# Contents of Volume 10

## No. 1-3

*T.K. Hughes, T.A. Kaspar and D.H. Coppenhaver (U.S.A.)*

Synergy of antiviral actions of TNF and IFN- $\gamma$ : evidence for a major role of TNF-induced IFN-B (AVR 00301)

1

*D.L. Taylor, L.E. Fellows, G.H. Farrar, R.J. Nash, D. Taylor-Robinson, M.A. Mobberley, T.A. Ryder, D.J. Jeffries and A.S. Tyms (U.K.)*

Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis (AVR 00302)

11

*E.H. Fennie, Y.S. Lie, M.-A.L. Low, P. Gribling and K.P. Anderson (U.S.A.)*

Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon- $\gamma$  treatment (AVR 00307)

27

*R.C. Reichman, J.P. Micha, Ph.K. Weck, W. Bonnez, D. Wold, J.K. Whisnant, P. Mounts, K.F. Trofatter, P. Kucera and S.A. Gall (U.S.A.)*

Interferon-alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy (AVR 00305)

41

*P. Cottagnoud, K.A. Neftel, M. Hany and R.M. Zinkernagel (Switzerland)*

Inhibition of HSV-1 and vaccinia virus replication by cephalosporin derivatives (AVR 00306)

59

*M. Campos, H. Bielefeldt Ohmann, G. Hughes, L.A. Babiuk and M.J.P. Lawman (Canada)*

Studies on the in vitro biological activities of recombinant bovine tumor necrosis factor (rBoTNF) alpha. I. Synergistic antiviral efficacy of rBoTNF alpha, recombinant bovine interferon gamma (rBoIFN gamma) and their combination (AVR 00304)

71

*M.G. Myers, D.I. Bernstein, C.J. Harrison and L.R. Stanberry (U.S.A.)*

Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs (AVR 00308)

83

*N.J. Burns, III, B.B. Barnett, J.H. Huffman, M.I. Dawson, R.W. Sidwell, E. De Clercq and M. Kende (U.S.A., Belgium)*

A newly developed immunofluorescent assay for determining the Pichinde virus-inhibitory effects of selected nucleoside analogues (AVR 00310)

89

*P. Wutzler, B. Helbig, A. Ulbricht, A. Meerbach and W. Pradel (G.D.R.)*

Therapeutic effect of pyrophosphate analogues on cutaneous herpes simplex virus type 1 infection in guinea pigs (AVR 00312)

99

*F. Ngan, R. Shihman Chang, H.D. Tappa and K.M. Smith (U.S.A.)*

Isolation, purification and partial characterization of an active anti-HIV compound from the Chinese medicinal herb *Viola yedoensis* (AVR 00311)

107

*C. Conti, N. Orsi and M.L. Stein (Italy)*

Effect of isoflavans and isoflavones on rhinovirus 1B and its replication in HeLA cells (AVR 00313)

117

*N.-G. Ilbäck, J. Fohlman and G. Friman (Sweden)*

The anti-inflammatory effect of LS 2616 and poly I:C in coxsackievirus B3 induced murine myocarditis (AVR 00315) 129

*P.G. Higgins, G.I. Barrow, W. Al-Nakib, D.A.J. Tyrrell, D.C. DeLong and I. Lenox-Smith (U.K.)*

Failure to demonstrate synergy between interferon- $\alpha$  and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers (AVR 00316) 141

Book Review 151

#### **No. 4-5**

*Y.-B. Kong, A.C. Scheck, R.W. Price, P.M. Vidal, M.P. Fanucchi, K.A. Watanabe, J.J. Fox and T.-C. Chou (U.S.A.)*

Incorporation and metabolism of 2'-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells (AVR 00318) 153

*S. Ikeda, Y. Kumuzawa, C. Nishimura, M. Nakatsuka, J.Y. Homma, M. Kiso and A. Hasegawa (Japan)*

Enhancement of nonspecific resistance to viral infection by chemically synthesized lipid A-subunit analogs with different backbone structures and acyl groups (AVR 00317) 167

*X.Q. Li, E. Gorelik, R.W. Atchison, A. Ovejera and M. Ho (U.S.A.)*

A new in vivo anti-viral assay using microencapsulated infected cell cultures (AVR 00320) 179

*R.W. Sidwell, J.H. Huffman, D.L. Barnard and D.Y. Pifat (U.S.A.)*

Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced *Phlebovirus* infections (AVR 00321) 193

*C.J. Harrison, L. Janski, T. Voychehovsky and D.I. Bernstein (U.S.A.)*

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection (AVR 00322) 209

*F.G. Hayden, D.J. Innes, Jr., S.E. Mills and P.A. Levine (U.S.A.)*

Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN- $\alpha$ Con<sub>1</sub> (AVR 00319) 225

*B.J. Terry, K.E. Mazina, A.V. Tuomari, M.L. Haffey, M. Hagen, A. Feldman, W.A. Slusarchyk, M.G. Young, R. Zahler and A.K. Field (U.S.A.)*

Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (*R,S*)-HPMPG (AVR 00323) 235

#### **No. 6**

*D.F. Smee, H.A. Alaghamandan, G.D. Kini and R.K. Robins (U.S.A.)*

Antiviral activity and mode of action of ribavirin 5'-sulfamate against Semlike Forest virus (AVR 00325) 253

*D.F. Smee, P.A. McKernan, H.A. Alaghamandan, K.B. Frank, K. Ramasamy, G.R. Revankar and R.K. Robins (U.S.A.)*

Antiviral activities of 2'-deoxyribofuranosyl and arabinofuranosyl analogs of sangivamycin against retro- and DNA viruses (AVR 00326) 263

*D.I. Bernstein, L.S. Loo and S. Kohl (U.S.A.)*

Antibody to cloned HSV glycoproteins B and D plus adult human leukocytes protect neonatal mice from lethal HSV infection (AVR 00328) 279

*M. Ito, A. Sato, K. Hirabayashi, F. Tanabe, S. Shigeta, M. Baba, E. De Clercq, H. Nakashima and N. Yamamoto (Japan, Belgium)*

Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV) (AVR 00329) 293

*S. Ikeda, K. Sai, C. Nishimura and A. Yamamoto (Japan)*

Antiherpes activity of the immunomodulator OK-432, a streptococcal preparation, in immunosuppressed mice (Short Communication) (AVR 00324) 299

Announcements 305

Contents of Volume 10 307

Author Index 311

Subject Index 314